Prostate-specific antigen (PSA) testing for prostate cancer has shifted the focus of diagnostic strategies from the evaluation of symptomatic men to the screening of asymptomatic men years before the disease is clinically evident. This evidence concerns the gene KLK3 and prostate cancer.